BPC-157 (Pentadecapeptide)

BPC-157 in the Published Literature

UKPWritten & reviewed by William Heath · Editor, UK Peptides research library2 min readLast reviewed 2026-08-234 cited sources

The short answer

The literature is dominated by preclinical work from the University of Zagreb group led by Predrag Sikirić, spanning gastrointestinal, tendon, ligament and vascular models. Clinical development occurred as PL-14736 for inflammatory bowel disease, and a Phase 2 trial is currently recruiting.

Key facts

Dominant source
Zagreb group (Sikirić and colleagues)
Evidence type
Predominantly rodent models
Clinical development
As PL-14736, for IBD
Phase 1
NCT02637284, 42 healthy volunteers
Phase 2 now
NCT07437547, 120 participants, recruiting
Independent replication
Limited

The shape of the evidence

Three tiers. A large preclinical literature, overwhelmingly in rats, covering gastrointestinal lesions, tendon and ligament models, vascular effects and more. An earlier clinical development programme under the code PL-14736. And one registered, placebo-controlled Phase 2 trial currently recruiting. Most research peptides have only the first tier; BPC-157 has all three, which is unusual.

The concentration of authorship

A substantial share of the preclinical literature originates from one group at the University of Zagreb. As with Pickart and GHK-Cu, this should be said clearly: sustained single-group work produces depth and preserves knowledge, and it also means the evidence is less independent than the paper count suggests, because shared methods and assumptions propagate through it. Independent replication is what converts findings into established results, and here it is limited.

Research material referenced

BPC-157 5mg, third-party HPLC tested

Buy BPC-157 · £16.95

What the clinical development tells you

A compound reaching Phase 1 and Phase 2 has passed the point where someone was willing to fund manufacturing to clinical standard, assemble a safety package and enrol human subjects under regulatory oversight. That is a meaningful filter. What it does not tell you is whether the compound works. Trials exist to answer that question, and the current one has not reported.

The status field worth reading correctly

NCT02637284, the Phase 1 study, carries status UNKNOWN on ClinicalTrials.gov. That means the record has not been verified by its sponsor recently; it does not mean the study failed, was withdrawn or found anything adverse. Reading UNKNOWN as a negative result is a common misinterpretation of registry data.

How to search it

PubMed indexes the field under BPC 157 and pentadecapeptide BPC. The development codes PL-14736 and PLD-116 surface the clinical literature that the compound name misses, just as thymosin beta-4 surfaces what TB-500 misses. ClinicalTrials.gov should be searched directly rather than relied on through secondary sources, because trial status changes.

Frequently asked questions

Has BPC-157 been tested in humans?

Yes. It entered clinical development as PL-14736 for inflammatory bowel disease, a Phase 1 study was registered, and a Phase 2 trial is currently recruiting.

What does UNKNOWN status mean on a trial record?

That the sponsor has not verified the record recently. It is not a statement about outcome, and reading it as failure is a misinterpretation.

Is the preclinical work independently replicated?

Limited. A substantial share originates from one group at the University of Zagreb, which makes the evidence less independent than the volume suggests.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and reviewed by

William Heath · Editor, UK Peptides research library

William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.

More BPC-157 (Pentadecapeptide) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.